Seres Therapeutics Is A Late Clinical Stage Biotechnology Company Dedicated To Developing Microbiome Based Therapeutics For Serious Diseases Linked To Microbial Imbalancesfounded In 2011 And Publicly Traded On Nasdaq Under The Ticker Mcrbthe Company Utilizes Its Ecobioticaplatform To Create Live Bacterial Consortia Aimed At Restoring Healthy Microbiome Function The Company Focuses On Treating Conditions Such As Recurrent Infections And Immune Mediated Gastrointestinal Disorders By Addressing Dysbiosiswhich Is The Imbalance Of Microbial Communitiesits Pipeline Includes Ser 109A Phase 3 Oral Therapeutic For Preventing Recurrentclostridium Difficileinfectionand Ser 262A Phase 1B Synthetic Microbiome Therapeuticseres Also Offers Vowsta Cthe First Fda Approved Oral Live Biotherapeutic For Cdi Preventionseres Therapeutics Primarily Serves Medically Vulnerable Populationsaiming To Reduce Reliance On Antibiotics And Meet The Needs Of Patients With Infectious And Immune Related Diseasesthe Company Is Committed To Advancing Microbiome Therapeutics As A Key Component Of Modern Medicine
